J Mult Scler Neuroimmunol.  2023 Jun;14(1):51-55. 10.59578/jmsni.2023.14.1.51.

Multiple Sclerosis in Korea: A Hospital-Based, Multicenter, Epidemiological Study

Affiliations
  • 1Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea
  • 2Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 3Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 4Department of Neurology, Seoul National University Hospital, Seoul, Korea
  • 5Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
  • 6Department of Neurology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 7Department of Neurology, Konkuk University Medical Center, Seoul, Korea
  • 8Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea
  • 9Department of Neurology, Korea University Anam Hospital, Seoul, Korea
  • 10Department of Neurology, Ajou University School of Medicine, Suwon, Korea
  • 11Department of Neurology, Seoul National University Boramae Hospital, Seoul, Korea
  • 12Parkminsu Neurology Clinic, Daegu, Korea
  • 13Department of Neurology, Chungnam National University Hospital, Daejeon, Korea
  • 14Department of Neurology, Chonnam National University Hospital, Korea
  • 15Department of Neurology, Jeonbuk National University Hospital, Jeonju, Korea
  • 16Department of Neurology, Kosin University College of Medicine, Busan, Korea
  • 17Department of Neurology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
  • 18Department of Neurology, Gachon University Gil Medical Center, Incheon, Korea
  • 19Department of Neurology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
  • 20Department of Neurology, Keimyung University Dongsan Hospital, Daegu, Korea
  • 21Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea
  • 22Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Pusan, Korea
  • 23Department of Neurology, Chosun University Hospital, Gwangju, Korea
  • 24Department of Neurology, Inha University Hospital, Incheon, Korea
  • 25Department of Neurology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
  • 26Department of Neurology, Kyung Hee University Medical Center, Seoul, Korea
  • 27Department of Neurology, Gyeongsang National University Changwon Hospital, Changwon, Korea
  • 28Department of Neurology, Jeonju Hospital, Jeonju, Korea
  • 29Department of Neurology, Korea University Ansan Hospital, Ansan, Korea
  • 30Department of Neurology, Seoul Medical Center, Seoul, Korea
  • 31Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

Abstract

Background
In the present era of rapidly evolving treatment options, there is a need for better understanding of the epidemiology and current management of patients with multiple sclerosis (MS). A survey was conducted to determine the epidemiologic characteristics and the current treatment status of patients with MS in Korea.
Methods
In April 2022, we collected data on patients with MS, including number participating in follow up, sex ratio, current disease modifying treatment (DMT), and disability status (Expanded Disability Status Score, EDSS) from 30 major MS centers in Korea.
Results
A total of 1,290 patients with MS was identified, with a female to male ratio of 2.4:1. Geographically, 1,047 patients (81%) were being monitored at hospitals in the capital regions (Seoul, Incheon, and Gyeonggi-do), while 243 (19%) were receiving care at hospitals outside the capital regions. There were 1,199 patients on DMTs, with 876 (73%) taking drugs with moderate efficacy and 264 (22%) taking drugs with high efficacy. Patients with current EDSS score greater than 3.0 and 5.5 numbered 242 (20%) and 105 (9%), respectively.
Conclusion
The hospital-based prevalence survey revealed the number and geographical distribution of patients with MS in Korea.

Keyword

Multiple sclerosis; Korea; Epidemiology; Disease-modifying therapies
Full Text Links
  • JMSNI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2025 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr